Drug Profile
Research programme: pulmonary fibrosis combination therapeutic - Biotherapix/Digna Biotech
Alternative Names: BTx201 and P17 combination therapeutic; M3 protein and P17 combination therapeuticLatest Information Update: 30 Jun 2011
Price :
$50
*
At a glance
- Originator Biotherapix; Digna Biotech
- Class
- Mechanism of Action Chemokine receptor antagonists; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pulmonary fibrosis
Most Recent Events
- 30 Jun 2011 Discontinued - Preclinical for Pulmonary fibrosis in Spain (unspecified route)
- 27 Feb 2007 Preclinical trials in Pulmonary fibrosis in Spain (unspecified route)